ApprovalTrail

Approval · Notice of Compliance 5 · 2004

ADDERALL XR: Notice of Compliance 5

Issued January 23, 2004

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
5
Date
January 23, 2004
Company
Shire Biochem Inc.Saint Laurent, Quebec, Canada
Product type
Prescription Pharmaceutical
Submission
New Drug Submission (NDS)
Submission class
Other
Therapeutic class
For attention deficit hyperactivity disorder

Products in this notice

BrandDINStatus today
ADDERALL XR02248809Marketed
ADDERALL XR02248811Marketed
ADDERALL XR02248813Marketed
ADDERALL XR02248808Marketed
ADDERALL XR02248810Marketed
ADDERALL XR02248812Marketed

Medicinal ingredients